Simplex Trading
PRLD icon

Simplex Trading’s Prelude Therapeutics PRLD Stock Holding History

Simplex Trading’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.2K Sell
5,600
-800
-13% -$2.1K ﹤0.01% 6817
2025
Q4 		$18.6K Buy
+6,400
New +$10.8K ﹤0.01% 6542
2024
Q3 		– Sell
-300
Closed -$1K – 9331
2024
Q2 		$1K Buy
+300
New +$1.22K ﹤0.01% 8529
2024
Q1 		– Sell
-300
Closed -$1K – 9655
2023
Q4 		$1K Buy
+300
New +$913 ﹤0.01% 8556
2022
Q4 		– Sell
-4,400
Closed -$29K – 10157
2022
Q3 		$29K Sell
4,400
-4,900
-53% -$33K ﹤0.01% 7114
2022
Q2 		$48K Buy
9,300
+400
+4% +$2.04K ﹤0.01% 6554
2022
Q1 		$61K Buy
8,900
+3,800
+75% +$34.8K ﹤0.01% 6858
2021
Q4 		$63K Buy
+5,100
New +$83K ﹤0.01% 6919

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Simplex Trading's PRLD Position: Q4 2025 in Review

Simplex Trading sold out of Prelude Therapeutics (PRLD) in Q4 2025, closing a stake of 153 shares — an estimated $258 sold.

Simplex Trading first reported a position in PRLD in Q1 2022 and held it in 8 quarters. The position peaked at $32K in Q1 2025. 48 funds tracked by Wall St. Rank hold PRLD as of Q4 2025.

  • Simplex Trading reported no remaining Prelude Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Simplex Trading sold 153 Prelude Therapeutics shares in Q4 2025, an estimated $258.
  • Simplex Trading first reported a position in Prelude Therapeutics in Q1 2022 and held it in 8 quarters.
  • Simplex Trading's Prelude Therapeutics position peaked at $32K in Q1 2025.
  • 48 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2025.

Based on Simplex Trading's 13F filing for Q4 2025, filed 11 Feb 2026.